The management of ACC of the scalp is still controversial. Our series suggests that conservative treatment should be performed for initial management in newborns.
Como citar este artigo: Mussi-Pinhata MM, Rego MA. Particularidades imunológicas do pré-termo extremo: um desafio para a prevenção da sepse hospitalar.
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of
chronic myeloid leukemia. Although most patients respond well to imatinib therapy,
the literature shows that one third develops resistance or intolerance. The timing of
second-line treatment after failure of initial treatment may have a significant
impact on long-term outcome. Thus, appropriate monitoring to identify resistance
and/or intolerance is crucial to early intervention with second generation tyrosine
kinase inhibitors and attainment of better results
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.